Tregzi (clinically known as Orca-T) is an allogeneic cellular immunotherapy consisting of purified regulatory and conventional T cells.

Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies for the potential risk for secondary T-cell ...

Hematologic malignancies encompass a diverse group of disorders characterised by the abnormal proliferation of blood-forming cells, including lymphomas, leukaemias and plasma cell dyscrasias. Although ...

Five-year overall survival (OS) for patients with de novo metastatic cancer increased from 10.6% in 1976-1981 to 23.6% in 2015-2020, representing more than a twofold improvement. Survival gains were ...

Integration of smartphone-based imaging and artificial intelligence (AI)-driven diagnostics provides an effective strategy ...

Financial Conflicts of Interest: Payment at the Expense of Patients? In the article that accompanies this editorial, Weisse et al 11 present new findings about residential hospice care for patients ...

Hematologic malignancies encompass a spectrum of cancers arising from blood-forming tissues, of which lymphomas represent a major subset originating in lymphoid cells. Advances in molecular profiling ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer “From a ...

Orca Bio, a commercial-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the U.S. Food and Drug Administration (FDA) has ...

Integration of smartphone-based imaging and artificial intelligence (AI)-driven diagnostics provides an effective strategy for screening for rare ocular malignancies, according to a study published ...